ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 2,150,000 shares, a decrease of 8.5% from the December 31st total of 2,350,000 shares. Based on an average daily volume of 252,300 shares, the short-interest ratio is currently 8.5 days.

Insider Buying and Selling

In related news, CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares of the company's stock, valued at $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,381 shares of company stock worth $2,441,556 in the last 90 days. Insiders own 12.70% of the company's stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. State Street Corp raised its stake in shares of ANI Pharmaceuticals by 9.1% in the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company's stock worth $41,991,000 after buying an additional 58,698 shares in the last quarter. Pacer Advisors Inc. raised its position in ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock valued at $33,907,000 after purchasing an additional 565,910 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after purchasing an additional 340,854 shares during the period. Global Alpha Capital Management Ltd. lifted its holdings in ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after acquiring an additional 9,500 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in ANI Pharmaceuticals by 4.2% during the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company's stock worth $25,373,000 after acquiring an additional 17,314 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Price Performance

ANIP stock traded up $1.23 during trading on Wednesday, hitting $59.82. The stock had a trading volume of 70,108 shares, compared to its average volume of 166,752. The stock has a market capitalization of $1.26 billion, a P/E ratio of -108.65 and a beta of 0.74. The company's 50-day moving average price is $56.61 and its two-hundred day moving average price is $58.48. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.05 earnings per share. As a group, research analysts predict that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an "overweight" rating and a $68.00 target price for the company. StockNews.com upgraded ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday. Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research note on Tuesday, October 22nd. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th. Finally, Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $77.71.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.